Additional license grant fees under agreement.

No definition available.

Name:	mgnx_AdditionalLicenseGrantFeesUnderAgreement
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Aggregate potential clinical milestone payments available to be earned under collaboration agreement.

+ References

No definition available.

+ Details

Name:	mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Aggregate potential regulatory and sales milestone payments available to be earned under collaboration agreement.

+ References

No definition available.

+ Details

Name:	mgnx_AdditionalPotentialRegulatoryAndSalesMilestonePaymentsUnderAgreement
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaboration and license agreement entered date.

+ References

No definition available.

+ Details

Name:	mgnx_CollaborationAndLicenseAgreementEnteredDate
Namespace Prefix:	mgnx_
Data Type:	us-types:dateStringItemType
Balance Type:	na
Period Type:	duration

- Definition

Deferred Revenue Current Remaining Balance

+ References

No definition available.

+ Details

Name:	mgnx_DeferredRevenueCurrentRemainingBalance
Namespace Prefix:	mgnx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Details

Name:	mgnx_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix:	mgnx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of molecules to be developed and commercialized as per collaborations.

+ References

No definition available.

+ Details

Name:	mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations
Namespace Prefix:	mgnx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront payment recognition period.

+ References

No definition available.

+ Details

Name:	mgnx_UpfrontPaymentRecognitionPeriod
Namespace Prefix:	mgnx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicensesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 28

-Section 50

-Paragraph 2

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

Collaboration and License Agreements - Additional Information 2 (Detail) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended
	Jan. 31, 2013 Molecule	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
License And Collaboration Agreements [Line Items]
Deferred revenue under agreement		$ 15,617,000		$ 15,617,000		$ 20,267,000
Gilead [Member]
License And Collaboration Agreements [Line Items]
Collaboration agreement date				January 2013
Commercialization of molecules	4
License grant fees		7,500,000		7,500,000
Expected period of development				21 months
Recognized revenue under agreement		1,000,000	2,200,000	5,500,000	5,900,000
Milestone achieved		0	0	0	0
Deferred revenue under agreement						3,600,000
Deferred revenue under agreement remaining		0		0
Gilead [Member] \| Minimum [Member]
License And Collaboration Agreements [Line Items]
Regulatory and sales milestone		240,000,000		240,000,000
Gilead [Member] \| Maximum [Member]
License And Collaboration Agreements [Line Items]
Regulatory and sales milestone		250,000,000		250,000,000
Gilead [Member] \| Pre-Clinical Milestones [Member] \| Minimum [Member]
License And Collaboration Agreements [Line Items]
Clinical milestone payments		20,000,000		20,000,000
Gilead [Member] \| Pre-Clinical Milestones [Member] \| Maximum [Member]
License And Collaboration Agreements [Line Items]
Clinical milestone payments		$ 25,000,000		$ 25,000,000